잠시만 기다려 주세요. 로딩중입니다.

CAR-T 세포 치료제

Chimeric Antigen Receptor-T Cell Therapy

대한내과학회지 2022년 97권 4호 p.229 ~ 237
변자민, 윤성수,
소속 상세정보
변자민 ( Byun Ja-Min ) - Seoul National University College of Medicine Department of Internal Medicine
윤성수 ( Yoon Sung-Soo ) - Seoul National University College of Medicine Department of Internal Medicine

Abstract


Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment.
During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.

키워드

Chimeric antigen receptor; CAR-T cell therapy; Lymphoma; Multiple myeloma

원문 및 링크아웃 정보

 

등재저널 정보